🇺🇸 Prednisone Taper in United States
52 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 52
Most-reported reactions
- Dyspnoea — 11 reports (21.15%)
- Pneumonia — 7 reports (13.46%)
- Condition Aggravated — 5 reports (9.62%)
- Pain — 5 reports (9.62%)
- Diarrhoea — 4 reports (7.69%)
- Nausea — 4 reports (7.69%)
- Pyrexia — 4 reports (7.69%)
- Rash — 4 reports (7.69%)
- Sinusitis — 4 reports (7.69%)
- Upper Respiratory Tract Infection — 4 reports (7.69%)
Other Immunology, Rheumatology, Endocrinology approved in United States
Frequently asked questions
Is Prednisone Taper approved in United States?
Prednisone Taper does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Prednisone Taper in United States?
Shilpa Grover, MD, MPH is the originator. The local marketing authorisation holder may differ — check the official source linked above.